Clinical Oncology
Volume 20, Issue 5 , Pages 325-326, June 2008

The HiLo Trial: a Multicentre Randomised Trial of High- versus Low-dose Radioiodine, with or without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation after Surgery for Differentiated Thyroid Cancer

  • U. Mallick

      Affiliations

    • Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle, UK
    • Corresponding Author InformationAuthor for correspondence: U. Mallick, Northern Centre for Cancer Treatment, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK.
    • ,
  • C. Harmer

      Affiliations

    • The Royal Marsden Hospital, London, UK
    • ,
  • A. Hackshaw

      Affiliations

    • Cancer Research UK & UCL Cancer Trials Centre, London, UK

Received 5 March 2008; accepted 10 March 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0936-6555(08)00151-9

doi:10.1016/j.clon.2008.03.010

Clinical Oncology
Volume 20, Issue 5 , Pages 325-326, June 2008

Article Tools